Literature DB >> 10741476

Measurement of furancarboxylic acid, a candidate for uremic toxin, in human serum, hair, and sweat, and analysis of pharmacological actions in vitro.

T Sassa1, H Matsuno, M Niwa, O Kozawa, N Takeda, T Niwa, T Kumada, T Uematsu.   

Abstract

3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), a candidate for uremic toxin, was measured in human hair for examining a possible utility as indicator of renal dysfunction. The serum concentration of CMPF was much higher (32.3 +/- 2.7 microg/ml, n = 17; mean +/- SEM) in uremic patients aged 40-55 years receiving hemodialysis treatment than in healthy younger subjects (3.61 +/- 0.19 microg/ml, n = 22), aged 18-23 years. However, the hair concentration of CMPF tended to be lower in the patients (6.8 +/- 1.7 ng/10 mg hair) than in the healthy younger subjects (15.8 +/- 4.5 ng/10 mg) and was significantly lower than that in the healthy age-matched subjects (22.4 +/- 5.3 ng/10 mg, n = 12), aged 40-47 years. Since CMPF was measurable in the sweat (4.4 +/- 3.7 ng/mg) collected from six out of seven healthy subjects examined, it was suggested that the contribution of sweat to the measurement of CMPF in hair was considerable. The fact that the uremic patients undergoing hemodialysis therapy had less sweat than healthy subjects may explain the lower concentration of CMPF in the patients' hair. The pathophysiological roles of CMPF in the body were attempted to be explored by using excised guinea pig organs, and human platelets and neutrophils. CMPF showed no remarkable effects in the concentration range of < or =10(-4) M except for only slight suppression of spontaneous contracture of guinea pig tenia coli at 10(-4) M. As far as the organs and tissues examined in the present study are concerned, the biological activity of CMPF itself, if any, may be very weak. Precaution should be taken against the delivery of a substance through sweat to hair when a small amount of substance is attempted to be measured in hair by employing a sensitive analytical method.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741476     DOI: 10.1007/s002040050020

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  9 in total

Review 1.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

Review 2.  Furan fatty acids: occurrence, synthesis, and reactions. Are furan fatty acids responsible for the cardioprotective effects of a fish diet?

Authors:  Gerhard Spiteller
Journal:  Lipids       Date:  2005-08       Impact factor: 1.880

3.  Association of advanced age with concentrations of uraemic toxins in CKD.

Authors:  Merita Rroji; Sunny Eloot; Annemie Dhondt; Wim Van Biesen; Griet Glorieux; Nathalie Neirynck; Nele Vandennoortgate; Sophie Liabeuf; Ziad Massy; Raymond Vanholder
Journal:  J Nephrol       Date:  2015-04-10       Impact factor: 3.902

4.  Distinct Influence of Omega-3 Fatty Acids on the Plasma Metabolome of Healthy Older Adults.

Authors:  Souzana-Eirini Xyda; Ivan Vuckovic; Xuan-Mai Petterson; Surendra Dasari; Antigoni Z Lalia; Mojtaba Parvizi; Slobodan I Macura; Ian R Lanza
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-04-17       Impact factor: 6.053

Review 5.  Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.

Authors:  Alexander J Prokopienko; Thomas D Nolin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-09-20       Impact factor: 5.045

6.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

7.  Evaluation of MASP1, CMPF and U.A serum levels in pre-diabetic subjects in comparison to Normal individuals for early diagnosis of subjects with pre-diabetes, a case-control study.

Authors:  Shohreh Fardipour; Soheila Moein; Saeed Hosseini Teshnizi; Mahmoud Khaytian; Durdi Qujeq
Journal:  J Diabetes Metab Disord       Date:  2020-11-21

8.  Platelet Function in CKD: A Systematic Review and Meta-Analysis.

Authors:  Constance C F M J Baaten; Marieke Sternkopf; Tobias Henning; Nikolaus Marx; Joachim Jankowski; Heidi Noels
Journal:  J Am Soc Nephrol       Date:  2021-05-03       Impact factor: 14.978

9.  Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients?

Authors:  Mathilde Luce; Anais Bouchara; Myriam Pastural; Samuel Granjon; Jean Christophe Szelag; Maurice Laville; Walid Arkouche; Denis Fouque; Christophe O Soulage; Laetitia Koppe
Journal:  Toxins (Basel)       Date:  2018-05-18       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.